Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 13 (May 1), 2008: pp. 2178-2185
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.8288

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by McDermott, D. F.
Right arrow Articles by Hersh, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDermott, D. F.
Right arrow Articles by Hersh, E.

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

David F. McDermott, Jeffrey A. Sosman, Rene Gonzalez, F. Stephen Hodi, Gerald P. Linette, Jon Richards, James W. Jakub, Muralidhar Beeram, Stefano Tarantolo, Sanjiv Agarwala, Gary Frenette, Igor Puzanov, Lee Cranmer, Karl Lewis, John Kirkwood, J. Michael White, Chenghua Xia, Kiran Patel, Evan Hersh

From the Beth Israel Deaconess Medical Center; Dana Farber Cancer Institute, Boston, MA; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Colorado Health Sciences Center, Aurora, CO; Washington University School of Medicine, St Louis, MO; Lutheran General Cancer Care Center, Park Ridge, IL; Lakeland Regional Cancer Center, Lakeland, FL; University of Texas Health Science Center, San Antonio, TX; Nebraska Methodist Hospital, Omaha, NB; St Luke's Health System, Bethlehem; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Carolinas Hematology-Oncology Associates, Charlotte, NC; University of Arizona Cancer Center, Tucson AZ; Onyx Pharmaceuticals, Inc, Emeryville, CA; and Bayer HealthCare Pharmaceuticals, West Haven, CT

Corresponding author: David F. McDermott, MD, Clinical Director of Biologic Therapy Program, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS-159, Boston, MA; e-mail: dmcdermo{at}bidmc.harvard.edu

Purpose: This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.

Patients and Methods: This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naïve patients with stage III (unresectable) or IV melanoma. A total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51). On day 1 of a 21-day cycle, patients received intravenous dacarbazine 1,000 mg/m2 for a maximum of 16 cycles. Oral sorafenib 400 mg or placebo was administered twice a day continuously. The primary end point was progression-free survival (PFS) by independent assessment. Secondary and tertiary end points included time to progression (TTP), response rate, and overall survival (OS).

Results: Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068). There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 weeks; HR, 0.619) in favor of the sorafenib plus dacarbazine arm. No difference in OS was observed (median, 51.3 v 45.6 weeks in the placebo plus dacarbazine and sorafenib plus dacarbazine arms, respectively; HR, 1.022). The regimen was well tolerated and had a manageable toxicity profile.

Conclusion: Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS. Based on these findings, additional studies with the combination are warranted in this patient population.

Supported by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc.

Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007 and at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.






About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online